Mortality and reduced growth hormone secretion

Area of Science:

• Endocrinology
• Epidemiology
• Public Health

Background:

• Limited data exist on mortality rates for patients with growth hormone deficiency (GHD), though hypopituitary patients show increased mortality compared to the general population.
• Cardiovascular disease is a suspected primary cause of death, with cancer statistics potentially affected by pituitary disease-related malignancies.
• Reported differences in mortality rates between females and males necessitate further investigation.

Purpose of the Study:

• To review and synthesize existing epidemiological data on mortality rates in hypopituitary and GHD patients.
• To identify potential factors influencing mortality, including sex and age of GHD onset.
• To evaluate the impact of growth hormone (GH) treatment on mortality rates.

Main Methods:

• Systematic review and analysis of published epidemiological studies focusing on mortality in hypopituitary and GHD populations.
• Inclusion of studies examining mortality in both treated and untreated GHD patients.

Main Results:

• Most reviewed studies indicate an elevated mortality rate in hypopituitary and GHD patients.
• Female patients generally exhibit higher mortality rates compared to male patients.
• Two studies suggest that GH treatment may lead to mortality rates comparable to the general population, though data are limited.

Conclusions:

• An increased mortality rate in hypopituitary patients is established, but definitive causes require further research.
• Interpreting the impact of GH treatment on mortality must be done cautiously due to limited data and study design constraints.
• Additional high-quality research is essential for accurate mortality estimations and understanding the role of GH therapy.